Lilly Deepens Lebanon Campus Investment with $4.5 Billion Commitment
Eli Lilly adds $4.5 billion to its Indiana manufacturing programme, funding a new genetic medicine facility and expanded API capacity at Lebanon, taking its total US investment since 2020 past $50 billion.
Eli Lilly recently announced an additional $4.5 billion investment across two of its three Lebanon sites—bringing the company's total Indiana capital expansion commitments since 2020 to more than $21 billion. Lilly's evolving pipeline, as well as anticipated demand for its medicines, prompted this additional commitment. The investment will incorporate new process designs and technologies at Lilly Lebanon API, one of the company's future active pharmaceutical ingredient sites, as well as Lilly Lebanon Advanced Therapies, its first dedicated genetic medicine manufacturing facility.
Lilly Lebanon Advanced Therapies is designed to support both clinical and commercial production of advanced therapies that target disease at the genetic level and will include a full spectrum of genetic medicine modalities from research-stage development through large-scale commercial supply. Designing and building for these modalities required developing new manufacturing processes without established commercial precedent. This facility is the first of three planned sites on the Lebanon campus, which will also include Lilly Lebanon API and the Lilly Medicine Foundry.
"Lilly's legacy of firsts in Indiana continues today—and the best measure of that legacy is what we do next," said David A. Ricks, Lilly chair and CEO. "From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world's most advanced plants to make them. When our Lebanon API site opens in 2027, it will be the largest API production site in US history, a commitment we chose to build here, at home."
Lilly's manufacturing investment extends well beyond its campus walls. According to a report that will be released next week by Indiana University's Kelley School of Business, Indiana Business Research Center, "Measuring Lilly's Economic and Civic Contributions in Indiana," Lilly accounts for 70% of Indiana's pharmaceutical GDP and every Lilly job supports more than two additional jobs across the state. Further, the company estimates that for every dollar it spends in the area, up to four dollars in additional local economic activity is generated.
Lilly's US capital expansion commitments since 2020 total more than $50 billion, investments made possible thanks to policies that promote domestic manufacturing. The company plans to break ground on several of its recently announced U.S. manufacturing sites this year.
